A patent granted for Medicortex

The granted patent (IL 268793) belongs to the company’s patent family titled “Non-invasive brain injury diagnostic device”. It protects a method and a simple handheld device based on a porous matrix for detecting company’s glycan-based biomarkers of TBI. Above all, the method and device are intended for probing non-invasive body fluid samples such as saliva enabling rapid detection of the head injury status after an incident in the field-testing conditions or even at home.

Medicortex has once again received confirmation of its strength in patent protecting the innovations and new technologies it has developed in-house by its experienced research team.

Dr. Harel, the CEO of Medicortex says: "The diagnostic kit being developed by Medicortex will enable a person to test themselves using a non-invasive body fluid sample such as urine or saliva to determine if an actual brain injury has occurred and if so, they will need to go to a hospital for further analysis. This kit makes an injured person aware of a brain trauma which will help decrease the risk for associated chronic conditions, as well as reduce the cost and time needed for diagnosis."

The company has received awards from the US Department of Defense’s medical research funds and is continuously submitting new research grant applications to advance the R&D project related to this invention. Medicortex is also open to private investments and information for interested investors is available at https://medicortex.fi/investors/.

Forward-looking statements

Certain statements in this communication are forward-looking statements. They are based on the views of the company’s management, as well as the understanding and assumptions of the company’s management based on the information available at present, and due to this, they may be forward-looking statements. Such forward-looking statements involve known and unknown risks, uncertainties and other important factors, which may result in that the company’s actual future results, operations, achievements and performance of the sector may differ significantly from the expectations conveyed in these statements. Forward-looking statements are not a guarantee of the company’s operational or financial performance in the future.